Information Provided By:
Fly News Breaks for June 14, 2018
HAE
Jun 14, 2018 | 08:25 EDT
Jefferies analyst Anthony Petrone raised his price target for Haemonetics to $110 after attending the global plasma meeting PPTA. Octapharma has selected a vendor which supports Haemonetics' fiscal 2019 guidance comments, Petrone tells investors in a research note. Further, his conversations at the conference confirmed that NexSys is being offered at a premium to PCS but also versus competition. The analyst sees a path to $140-$150 for shares over time and keeps a Buy rating on Haemonetics.
News For HAE From the Last 2 Days
There are no results for your query HAE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.